Rockford Coscia
View Rockford Coscia's Articles BY TICKER:
- Vivus Planning for Failure in Qnexa Birth Defect Study
- Xenoport Expecting GERD Study Data
- MannKind Is Teetering on the Brink of Disaster
- NDA Decision Delay May Be Good for MannKind, Not for Human Genome Sciences
- Arena Completes End-Of-Review Meeting With FDA
- Clinical Data's Vilazodone Offers Possible Blockbuster Returns
- Orexigen's Contrave Obesity Drug Heads to FDA Panel: Analyzing the Safety Issues
- Buyout or No, Delcath Offers a Valuable Investment Opportunity
- Avanir's AVP-923: Is QTc Prolongation Above 'Threshold of Concern'?
- What Amylin's Diabetes Treatment Complete Response Letter Means for Avanir
- Alexza's CRL Offers Long Term Investment Opportunity
- Alexza Pharmaceuticals: Hold, Sell, Or Put?
- Biodel: Upside from Potential Linjeta Approval
- Vivus' Qnexa Panel: What Might Have Been
- Avanir: Insider Selling and Shelf Registration Are No Big Deal
- Avanir Pharma's Pending FDA Approval: The Upside Potential
- Arena’s Lorcaserin: What Now?
- Arena Pharmaceutical's Lorqess: A Briefing Document Analysis
- Arena’s Lorqess: A Market Size Analysis
- Vivus' Qnexa Panel Bodes Well for Arena's Obesity Drug
- Five Potential Small Cap Biotech Bargains
- Why Cumberland Pharma Needs Acetadote Approval to Avert Disaster
- A Reintroduction to Savient's Krystexxa
- Arena's Obesity Drug Likely to Pass FDA Panel With Flying Colors
- Jazz: Your FDA Panel Primer
-
Will MannKind's Afrezza Succeed Where Pfizer's Exubera Failed?